标题
Proteasome inhibitors in the treatment of multiple myeloma
作者
关键词
-
出版物
LEUKEMIA
Volume 23, Issue 11, Pages 1964-1979
出版商
Springer Nature
发表日期
2009-09-10
DOI
10.1038/leu.2009.173
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
- (2010) Marianne S. Poruchynsky et al. CELL CYCLE
- Antioxidants block proteasome inhibitor function in endometrial carcinoma cells
- (2009) David Llobet et al. ANTI-CANCER DRUGS
- Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
- (2009) E. B. Golden et al. BLOOD
- Bortezomib and EGCG: no green tea for you?
- (2009) J. J. Shah et al. BLOOD
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
- (2009) J. R. Berenson et al. CLINICAL CANCER RESEARCH
- Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen
- (2009) James R. Berenson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
- (2009) T Rückrich et al. LEUKEMIA
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center
- (2009) Yujun Dong et al. LEUKEMIA & LYMPHOMA
- Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
- (2008) James R. Berenson et al. ANNALS OF HEMATOLOGY
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
- (2008) A. Palumbo et al. ANNALS OF ONCOLOGY
- Signals that maintain leukemic cell viability
- (2008) J. Plate BLOOD
- Many facets of bortezomib resistance/susceptibility
- (2008) S. Kumar et al. BLOOD
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
- (2008) Deborah J. Kuhn et al. BLOOD
- Glucose, insulin, coagulation: endotoxin as exohormone
- (2008) J. C. Marshall BLOOD
- Ligandless receptors find a role
- (2008) T. J. Hamblin BLOOD
- Biology, treatment, and time
- (2008) A. Dispenzieri BLOOD
- A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
- (2008) L. Rosinol et al. BLOOD
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1
- (2008) D. H. Shin et al. BLOOD
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC/Ca2+ signaling pathways
- (2008) C. M. Yoon et al. BLOOD
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
- (2008) A. A. Argyriou et al. BLOOD
- Targeting the UPS as therapy in multiple myeloma
- (2008) Dharminder Chauhan et al. BMC BIOCHEMISTRY
- Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
- (2008) G L Uy et al. BONE MARROW TRANSPLANTATION
- Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
- (2008) Rakesh Popat et al. BRITISH JOURNAL OF HAEMATOLOGY
- The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
- (2008) Stefania Ciolli et al. BRITISH JOURNAL OF HAEMATOLOGY
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
- (2008) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
- (2008) Pieter Sonneveld et al. CANCER
- Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma
- (2008) John D. Hainsworth et al. CANCER
- Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy
- (2008) Eric Vickrey et al. CANCER
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
- (2008) R. Z. Orlowski et al. CLINICAL CANCER RESEARCH
- Immune-mediated neuropathies in myeloma patients treated with bortezomib
- (2008) Sabrina Ravaglia et al. CLINICAL NEUROPHYSIOLOGY
- NF-??B in the pathogenesis and treatment of multiple myeloma
- (2008) Zhi-Wei Li et al. CURRENT OPINION IN HEMATOLOGY
- Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line
- (2008) Shuqing Lü et al. EXPERIMENTAL HEMATOLOGY
- High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
- (2008) J. El-Cheikh et al. HAEMATOLOGICA
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
- (2008) M.-V. Mateos et al. HAEMATOLOGICA
- Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
- (2008) Donna E. Reece et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
- (2008) Bruce D. Dorsey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Point Mutation of the Proteasome 5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
- (2008) S. Lu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Treatment of plasma cell dyscrasias with lenalidomide
- (2008) M A Dimopoulos et al. LEUKEMIA
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
- (2008) E Terpos et al. LEUKEMIA
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
- (2008) J F San-Miguel et al. LEUKEMIA
- VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
- (2008) M Pineda-Roman et al. LEUKEMIA
- Bortezomib-associated tumor lysis syndrome in multiple myeloma
- (2008) Michelle Furtado et al. LEUKEMIA & LYMPHOMA
- Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
- (2008) David T Yang et al. Molecular Cancer
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
- (2008) K Hatano et al. ONCOGENE
- Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)
- (2007) Lauren M. Congdon et al. BIOCHEMICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now